SCHEMBL2960946

SCHEMBL2960946

Cc1ccc(Sc2ccc(O)cc2)c(Nc2ccnc3ncccc23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 4/20 0.41
MAPKAPK2 P49137 1/20 0.39
PIM1 P11309 1/20 0.38
AKT2 P31751 1/20 0.38
RET P07949 2/20 0.35
RIPK1 Q13546 1/20 0.35
RIPK3 Q9Y572 1/20 0.35
KDR P35968 3/20 0.35
MAPK14 Q16539 2/20 0.35
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 3/20 0.34
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
VCAM1 P19320 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955730 0.90 L3MBTL1 (0.36) RIPK2MAPKAPK2ALDH1A1MEN1KMT2A
SCHEMBL2015588 0.87 PIM1 (0.49) RIPK2MAPKAPK2PIM1AKT2RET
SCHEMBL810693 0.86 PIM1 (0.52) PIM1AKT2RETKDRMEN1
SCHEMBL2969920 0.85 BLM (0.41) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL2021349 0.85 PIM1 (0.40) RIPK2MAPKAPK2PIM1AKT2RET
SCHEMBL2019804 0.84 PIM1 (0.41) RIPK2MAPKAPK2PIM1AKT2RET
SCHEMBL2968398 0.83 PIM1 (0.41) RIPK2MAPKAPK2PIM1AKT2RET
SCHEMBL2957245 0.83 PIM1 (0.39) RIPK2MAPKAPK2PIM1AKT2RET
SCHEMBL811358 0.83 MAPKAPK2 (0.36) RIPK2MAPKAPK2PIM1AKT2RET
SCHEMBL2961869 0.82 PIM1 (0.42) RIPK2MAPKAPK2PIM1AKT2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 RIPK2 3496/4885MAPKAPK2 3663/4885PIM1 2963/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 RIPK2 3496/4885MAPKAPK2 3663/4885PIM1 2963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.